Clinical and Biological Impact of Caffeine Therapy in Premature Infants

A prospective observational study of 325 premature neonates conducted to evaluate caffeine citrate therapy for apnea of prematurity. The dataset includes 75 infants receiving caffeine, divided into high and normal serum concentration groups, and 250 infants in a comparison group. It was authored by Adela-Valeria Neamțu and last updated in May 2026.

Use Cases

• Analyzing the relationship between serum caffeine citrate concentration and clinical outcomes based on the monitored titer levels.
• Comparing adverse event rates like intracranial hemorrhage and convulsions between treatment and control groups.
• Investigating the role of therapeutic drug monitoring in individualizing dosing for apnea of prematurity.

Strengths

• Includes data from 325 premature neonates, providing a substantial sample size for a clinical study.
• Prospective observational design with clearly defined groups: 25 high-concentration, 50 normal-concentration, and 250 comparison patients.
• Dynamically monitored serum caffeine citrate concentrations, a key feature for pharmacokinetic analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for specific analytical tasks.
• The data is contained in a 118.5 KB DOCX file, suggesting limited scope and potentially non-tabular or summary format.

Provenance

Source

figshare

Collection Method

Prospective observational clinical study.

Freshness

Last updated 2026-05-13 05:56:39; freshness should be verified.